StockData

Lycia Therapeutics, Inc. (LYCA) company profile

LYCANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$31.35+0.43 (+1.39%)

Close on Nov 18, 2026Market cap –P/E –Yield –

About Lycia Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Lycia Therapeutics, Inc. is listed on Nasdaq under the ticker LYCA, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31.

Company profile

Company

Legal name
Lycia Therapeutics, Inc.
Headquarters
South San Francisco, CA
Address
400 East Jamie Court, Suite 200 94080
Phone
(650) 392-3357
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31

Stock & identifiers

Ticker
LYCA
Exchange
Nasdaq
SEC CIK
1806540
CUSIP
55081P100
ISIN
US55081P1003
FIGI
BBG00VDDDFT9
Share class FIGI
BBG00VDDDFV6
EIN
84-3860514

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Aetna Wun TrombleyPresident and CEO, Director415,255
Steven StabenChief Scientific Officer55,448
Amy BachrodtChief Financial Officer–
Chin Hyok LeeChief Medical Officer–
Sofia TouamiChief Business Officer–
William Jl RieflinDirector89,781
Jane HendersonDirector–
Laurent FischerDirector33,269

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 20, 2026ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?